NGHIÊN CỨU KẾT QUẢ KIỂM SOÁT NỒNG ĐỘ GALECTIN-3 MÁU BẰNG SPIRONOLACTON Ở BỆNH NHÂN SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM

Abstract

Objective: The current prospective study was conducted to evaluate the results of controlling galectin-3 levels with spironolactone in patients with heart failure and reduced ejection fraction. Subjects and methods: A cross-sectional descriptive study on 122 patients with heart failure and reduced ejection fraction admitted to Cardiovascular in Can Tho city from 2018 to 2019. Results: In 122 patients, the rate of women is higher than men (55.7/44.3%). The ages of 50-69 years old accounted for the highest with 59.83% and the lowest group, with 31-49 years old. The rate of increased galectin-3 was 88.52%. After treatment with spironolactone, the galectin-3 concentration decreased when compared to before treatment according to three levels of hypertension, the New York Heart Association classification (p<0.05), after 12 weeks of treatment, galectin-3 decreased the most by 29.05% with the dose of spironolactone was 50mg compared with spironolactone 25mg, the difference was statistically significant (p<0.01). Conclusion: The incidence of hyper galectin-3 in patients with heart failure and reduced ejection fraction was high. Moreover, the treatment with spironolactone markedly decreased galectin-3 levels after 12 weeks.